A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer

NCT06713564 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancers

Interventions

DRUG: LS301-IT

Sponsor

Integro Theranostics